Liposomal Doxorubicin: A Review of its Use in Metastatic Breast Cancer and Potential in Non-Hodgkin Lymphoma

Authors: Dando, Toni M.; Keating, Gillian M.

Source: American Journal of Cancer, Volume 4, Number 3, 2005 , pp. 193-206(14)

Buy & download fulltext article:

Price: $57.95 plus tax (Refund Policy)

Abstract:

Liposomal doxorubicin (Myocet^™) has been developed with the aim of improving the therapeutic index of the anthracycline doxorubicin by reducing the drug's cardiotoxicity, but maintaining its antitumor efficacy. Liposomal doxorubicin plus cyclophosphamide is no less effective than conventional doxorubicin or epirubicin plus cyclophosphamide in the first-line treatment of women with metastatic breast cancer. In addition, the drug is significantly less cardiotoxic than conventional doxorubicin. The median cumulative dose to the first cardiac event for liposomal doxorubicin is higher than that for conventional doxorubicin; the potential to use doxorubicin for a longer period of time may benefit a number of patients. Liposomal doxorubicin has also shown potential as part of a chemotherapy regimen in patients with non-Hodgkin lymphoma (NHL). Thus, liposomal doxorubicin represents an important advance in terms of offering reduced cardiotoxicity compared with conventional doxorubicin, and can be used in preference to conventional doxorubicin in a combination regimen with cyclophosphamide in the first-line treatment of patients with metastatic breast cancer.

Keywords: Adis Drug Evaluations; Breast cancer; Cytostatic antibiotics; Doxorubicin liposomal; Non Hodgkin's lymphoma

Document Type: Research article

Affiliations: 1: Adis International Inc., Yardley, Pennsylvania, USA

Publication date: 2005-01-01